U.S. market Closed. Opens in 4 hours 35 minutes

DHR | Danaher Corporation Stock Overview

(Stock Exchange: NYSE)
Day's Range 228.89 - 233.73
52 Week Range 215.68 - 281.70
Beta 0.85
Implied Volatility 24.47%
IV Rank 11.92%
Day's Volume 2,136,269
Average Volume 2,561,945
Shares Outstanding 722,275,000
Market Cap 168,362,302,500
Sector Healthcare
Industry Medical - Diagnostics & Research
IPO Date 1978-12-29
Valuation
Profitability
Growth
Health
P/E Ratio 43.90
Forward P/E Ratio 29.73
EPS 5.31
1YR Price Target 290.00
Dividend Yield 0.47%
Dividend Per Share 0.68
Dividend ExDate 2023-06-29
Dividend PayDate 2023-07-28
Employees 61,000
Country USA
Website DHR
Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
DHR's peers: A, ILMN, IDXX, WAT, TMO, MTD, CRL, NVTA, GH, RVTY, EXAS, FLGT, ME, TTOO, TWST
*Chart delayed
Analyzing fundamentals for DHR we got that it has average fundamentals where Valuation is considered to be overvalued, Profitability is poor, Growth is good and Health is passable. For more detailed analysis please see DHR Fundamentals page.

Watching at DHR technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on DHR Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙